OBJECTIVES: We applied the cardiovascular angiography and interventions (SCAI) shock staging system to patients presenting with acute myocardial infarction and cardiogenic shock (AMI-CS) who were enrolled in the National Cardiogenic Shock Initiative (NCSI). BACKGROUND: The SCAI shock staging system provides a framework for evaluation of patients with CS based on clinical and hemodynamic parameters, but has not been validated in patients with AMI-CS managed with a contemporary treatment algorithm that incorporates early use of Impella. METHODS: Consecutive patients enrolled in NCSI were identified, all of whom were managed with invasive hemodynamic guidance and supported with Impella. Patients were retrospectively categorized into appropriate SCAI shock stages, and outcomes were assessed accordingly. RESULTS: A total of 300 patients were included in the analysis; 182 patients (61%) presented in Stage C shock, 25 (8%) in Stage D, and 93 (31%) in Stage E. Survival to hospital discharge was 76, 76, and 58%, respectively (p = .006). Survival was <20% among patients in Stage E at 24 hr, regardless of baseline stage. There was near perfect agreement in shock staging between two independent clinicians at baseline (kappa = 0.975, 95% CI, 0.95-1.00, p < .001) and at 24 hr (kappa = 0.985, 95% CI, 0.77-1.00, p < .001). CONCLUSION: In patients with AMI-CS enrolled in NCSI, SCAI Shock classification was reproducible, and predicted survival when applied at presentation and at 24 hr.
OBJECTIVES: We applied the cardiovascular angiography and interventions (SCAI) shock staging system to patients presenting with acute myocardial infarction and cardiogenic shock (AMI-CS) who were enrolled in the National Cardiogenic Shock Initiative (NCSI). BACKGROUND: The SCAI shock staging system provides a framework for evaluation of patients with CS based on clinical and hemodynamic parameters, but has not been validated in patients with AMI-CS managed with a contemporary treatment algorithm that incorporates early use of Impella. METHODS: Consecutive patients enrolled in NCSI were identified, all of whom were managed with invasive hemodynamic guidance and supported with Impella. Patients were retrospectively categorized into appropriate SCAI shock stages, and outcomes were assessed accordingly. RESULTS: A total of 300 patients were included in the analysis; 182 patients (61%) presented in Stage C shock, 25 (8%) in Stage D, and 93 (31%) in Stage E. Survival to hospital discharge was 76, 76, and 58%, respectively (p = .006). Survival was <20% among patients in Stage E at 24 hr, regardless of baseline stage. There was near perfect agreement in shock staging between two independent clinicians at baseline (kappa = 0.975, 95% CI, 0.95-1.00, p < .001) and at 24 hr (kappa = 0.985, 95% CI, 0.77-1.00, p < .001). CONCLUSION: In patients with AMI-CS enrolled in NCSI, SCAI Shock classification was reproducible, and predicted survival when applied at presentation and at 24 hr.
Authors: Rasha Kaddoura; Amr Elmoheen; Ehab Badawy; Mahmoud F Eltawagny; Mohamed A Seif; Khalid Bashir; Amar M Salam Journal: J Drug Assess Date: 2021-07-20
Authors: Nanna Louise Junker Udesen; Ole Kristian Lerche Helgestad; Jakob Josiassen; Christian Hassager; Henrik Frederiksen Højgaard; Louise Linde; Jesper Kjaergaard; Lene Holmvang; Lisette Okkels Jensen; Henrik Schmidt; Hanne Berg Ravn; Jacob Eifer Møller Journal: PLoS One Date: 2022-08-04 Impact factor: 3.752
Authors: Héctor González-Pacheco; Rodrigo Gopar-Nieto; Diego Araiza-Garaygordobil; José Luis Briseño-Cruz; Guering Eid-Lidt; Jorge Arturo Ortega-Hernandez; Daniel Sierra-Lara; Alfredo Altamirano-Castillo; Salvador Mendoza-García; Daniel Manzur-Sandoval; Klayder Melissa Aguilar-Montaño; Heriberto Ontiveros-Mercado; Jorge Iván García-Espinosa; Pablo Esteban Pérez-Pinetta; Alexandra Arias-Mendoza Journal: PLoS One Date: 2022-08-16 Impact factor: 3.752
Authors: Dirk von Lewinski; Lukas Herold; Christian Stoffel; Sascha Pätzold; Friedrich Fruhwald; Siegfried Altmanninger-Sock; Ewald Kolesnik; Markus Wallner; Peter Rainer; Heiko Bugger; Nicolas Verheyen; Ursula Rohrer; Martin Manninger-Wünscher; Daniel Scherr; Dietmar Renz; Ameli Yates; Andreas Zirlik; Gabor G Toth Journal: Catheter Cardiovasc Interv Date: 2022-07-13 Impact factor: 2.585
Authors: Adamantios Tsangaris; Tamas Alexy; Rajat Kalra; Marinos Kosmopoulos; Andrea Elliott; Jason A Bartos; Demetris Yannopoulos Journal: Front Cardiovasc Med Date: 2021-07-07